Multi-National Company (MNC)

You are an international consultant and have been asked to help a large multinational organization develop the criteria for a new position: Global Ethics Director (GED). Your paper will be given to the CEO and senior leadership representatives from five countries where the organization has offices. These countries are the United States, Denmark, South Africa, New Zealand, and Brazil

Assume that your Multi-National Company (MNC) has experienced negative press for its poor sustainability and ethics record in the past. Create a logical scenario and describe what the MNC did poorly, the impact of that poor performance, and what needs to be corrected. Base your answers to the following on that scenario

Assess the potential role of the GED in each of the MNC’s locations, above. To do so, you will need to analyze why and how this role is critically important to the MNC.
What credentials and experience do you recommend be required for the GED position, keeping in mind the cultural and socio-political differences among the five countries.
Devise a plan for how the new GED should establish and maintain relationships with each of the MNC’s international offices.
Formulate performance metrics for the position and describe how the position will be monitored.

Sample Solution

causing discomfort and decreased quality of life. About 10-15% of women experience episodes of DUB at sometime during the reproductive years of their lives. Annually 5-19% of women seek medical care. It accounts for more than 25% of all hysterectomies. A wide range of treatment modalities are available.
OBJECTIVES: To study efficacy of oral ormeloxifene and levonorgesterol IUCD in terms of blood loss, endometrial thickness, hemoglobin concentration and to evaluate side effects in DUB.
METHODS: 80 women presenting with dysfunctional uterine bleeding were allocated to 2 equal groups, group1: received 60mg oral ormeloxifene twice a week for 12 weeks and once a week for next 12weeks. Group2: received levonorgesterol IUCD. The primary outcomes were reduction in menstrual blood loss( measured by fall in PBAC score), rise in hemoglobin levels, decrease in endometrial thickness. The follow up was done at 3rd and 6th month.
RESULTS: This study shows significant reduction in PBAC scores with use of ormeloxifene (P=<0.001) and also with Levonorgestrel IUCD (P=<0.001), hence reduction in blood loss. Significant increase in hemoglobin concentration with ormeloxifene (P=<0.001) and levonorgestrel IUCD (P=0.002) and decrease in endometrial thickness with ormeloxifene (P=<0.001) and levonorgestrel IUCD (P=<0.001). No statistical significant between the two groups.
CONCLUSION: Both ormeloxifene and levonorgestrel IUCD are equally efficacious and safe. Ormeloxifene is preferred for treatment of DUB as it is easy to administer and cheap compared to levonorgestrel IUCD which is costly and with few side effects like spotti

This question has been answered.

Get Answer
WeCreativez WhatsApp Support
Our customer support team is here to answer your questions. Ask us anything!
👋 Hi, Welcome to Compliant Papers.